153 related articles for article (PubMed ID: 27698843)
1. Functional redundancy of the Notch pathway in ovarian cancer cell lines.
Silva F; Félix A; Serpa J
Oncol Lett; 2016 Oct; 12(4):2686-2691. PubMed ID: 27698843
[TBL] [Abstract][Full Text] [Related]
2. Trends in the Incidence and Survival Rates of Primary Ovarian Clear Cell Carcinoma Compared to Ovarian Serous Carcinoma in Korea.
Kim SI; Ha HI; Eoh KJ; Lim J; Won YJ; Lim MC
Front Oncol; 2022; 12():874037. PubMed ID: 35463304
[TBL] [Abstract][Full Text] [Related]
3. Correlation of
Kim MJ; Kim AR; Jeong JY; Kim KI; Kim TH; Lee C; Chung K; Ko YH; An HJ
J Cancer; 2017; 8(16):3331-3342. PubMed ID: 29158806
[No Abstract] [Full Text] [Related]
4. Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications.
Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMullan C; Miller JW; Marks PA; Mitsiades N
Invest Ophthalmol Vis Sci; 2009 Sep; 50(9):4072-9. PubMed ID: 19387079
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
[TBL] [Abstract][Full Text] [Related]
6. Delta-like 1 homologue promotes tumorigenesis and epithelial-mesenchymal transition of ovarian high-grade serous carcinoma through activation of Notch signaling.
Huang CC; Cheng SH; Wu CH; Li WY; Wang JS; Kung ML; Chu TH; Huang ST; Feng CT; Huang SC; Tai MH
Oncogene; 2019 Apr; 38(17):3201-3215. PubMed ID: 30626939
[TBL] [Abstract][Full Text] [Related]
7. Current and future strategies for treatment of ovarian clear cell carcinoma.
Ogasawara A; Sato S; Hasegawa K
J Obstet Gynaecol Res; 2020 Sep; 46(9):1678-1689. PubMed ID: 32578333
[TBL] [Abstract][Full Text] [Related]
8. Targeting STAT3 by HO3867 induces apoptosis in ovarian clear cell carcinoma.
Bixel K; Saini U; Kumar Bid H; Fowler J; Riley M; Wanner R; Deepa Priya Dorayappan K; Rajendran S; Konishi I; Matsumura N; Cohn DE; Selvendiran K
Int J Cancer; 2017 Nov; 141(9):1856-1866. PubMed ID: 28646535
[TBL] [Abstract][Full Text] [Related]
9. Notch signaling in serous ovarian cancer.
Groeneweg JW; Foster R; Growdon WB; Verheijen RH; Rueda BR
J Ovarian Res; 2014 Nov; 7():95. PubMed ID: 25366565
[TBL] [Abstract][Full Text] [Related]
10. Targeting CD146 in combination with vorinostat for the treatment of ovarian cancer cells.
Ma X; Wang J; Liu J; Mo Q; Yan X; Ma D; Duan H
Oncol Lett; 2017 Mar; 13(3):1681-1687. PubMed ID: 28454309
[TBL] [Abstract][Full Text] [Related]
11. Notch- and vitamin D signaling in 1,25(OH)2D3-resistant glioblastoma multiforme (GBM) cell lines.
Reichrath S; Müller CS; Gleissner B; Pfreundschuh M; Vogt T; Reichrath J
J Steroid Biochem Mol Biol; 2010 Jul; 121(1-2):420-4. PubMed ID: 20206691
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: does timing matter?
Modesitt SC; Parsons SJ
Gynecol Oncol; 2010 Nov; 119(2):351-7. PubMed ID: 20673975
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of Notch ligands in patients with non-small cell lung cancer.
Pancewicz-Wojtkiewicz J; Eljaszewicz A; Kowalczuk O; Niklinska W; Charkiewicz R; Kozłowski M; Miasko A; Moniuszko M
Oncol Lett; 2017 Jan; 13(1):506-510. PubMed ID: 28123589
[TBL] [Abstract][Full Text] [Related]
14. Suberoylanilide hydroxamic Acid, a histone deacetylase inhibitor, alters multiple signaling pathways in hepatocellular carcinoma cell lines.
Kunnimalaiyaan S; Sokolowski K; Gamblin TC; Kunnimalaiyaan M
Am J Surg; 2017 Apr; 213(4):645-651. PubMed ID: 28007318
[TBL] [Abstract][Full Text] [Related]
15. Notch ligand Delta-like 1 as a novel molecular target in childhood neuroblastoma.
Bettinsoli P; Ferrari-Toninelli G; Bonini SA; Prandelli C; Memo M
BMC Cancer; 2017 May; 17(1):352. PubMed ID: 28525978
[TBL] [Abstract][Full Text] [Related]
16. The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma.
Oishi T; Itamochi H; Kudoh A; Nonaka M; Kato M; Nishimura M; Oumi N; Sato S; Naniwa J; Sato S; Shimada M; Kigawa J; Harada T
Oncol Rep; 2014 Aug; 32(2):553-8. PubMed ID: 24927217
[TBL] [Abstract][Full Text] [Related]
17. PP242 synergizes with suberoylanilide hydroxamic acid to inhibit growth of ovarian cancer cells.
Qin Y; Zhao X; Fang Y
Int J Gynecol Cancer; 2014 Oct; 24(8):1373-80. PubMed ID: 25188886
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of PI3K/AKT/mTOR and MAPK signaling pathways decreases progranulin expression in ovarian clear cell carcinoma (OCCC) cell line: a potential biomarker for therapy response to signaling pathway inhibitors.
Perez-Juarez CE; Arechavaleta-Velasco F; Zeferino-Toquero M; Alvarez-Arellano L; Estrada-Moscoso I; Diaz-Cueto L
Med Oncol; 2019 Nov; 37(1):4. PubMed ID: 31713081
[TBL] [Abstract][Full Text] [Related]
19. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract][Full Text] [Related]
20. Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.
Chan KK; Wong OG; Wong ES; Chan KK; Ip PP; Tse KY; Cheung AN
Int J Cancer; 2018 Sep; 143(6):1456-1469. PubMed ID: 29663364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]